Goldman Sachs Initiates Coverage On City Therapeutics with Early-Stage Biotech Rating
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsInitiation
Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.
Goldman Sachs analyst Salveen Richter initiates coverage on City Therapeutics (NASDAQ:CTY) with a Early-Stage Biotech rating.